Urinary phenotyping of SARS-CoV-2 infection connects clinical diagnostics with metabolomics and uncovers impaired NAD+ pathway and SIRT1 activation

The stratification of individuals suffering from acute and post-acute SARS-CoV-2 infection remains a critical challenge. Notably, biomarkers able to specifically monitor viral progression, providing details about patient clinical status, are still not available. Herein, quantitative metabolomics is...

Full description

Saved in:
Bibliographic Details
Published inClinical chemistry and laboratory medicine Vol. 62; no. 4; pp. 770 - 788
Main Authors Lonati, Caterina, Berezhnoy, Georgy, Lawler, Nathan, Masuda, Reika, Kulkarni, Aditi, Sala, Samuele, Nitschke, Philipp, Zizmare, Laimdota, Bucci, Daniele, Cannet, Claire, Schäfer, Hartmut, Singh, Yogesh, Gray, Nicola, Lodge, Samantha, Nicholson, Jeremy, Merle, Uta, Wist, Julien, Trautwein, Christoph
Format Journal Article
LanguageEnglish
Published Germany De Gruyter 25.03.2024
Walter De Gruyter & Company
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The stratification of individuals suffering from acute and post-acute SARS-CoV-2 infection remains a critical challenge. Notably, biomarkers able to specifically monitor viral progression, providing details about patient clinical status, are still not available. Herein, quantitative metabolomics is progressively recognized as a useful tool to describe the consequences of virus-host interactions considering also clinical metadata. The present study characterized the urinary metabolic profile of 243 infected individuals by quantitative nuclear magnetic resonance (NMR) spectroscopy and liquid chromatography mass spectrometry (LC-MS). Results were compared with a historical cohort of noninfected subjects. Moreover, we assessed the concentration of recently identified antiviral nucleosides and their association with other metabolites and clinical data. Urinary metabolomics can stratify patients into classes of disease severity, with a discrimination ability comparable to that of clinical biomarkers. Kynurenines showed the highest fold change in clinically-deteriorated patients and higher-risk subjects. Unique metabolite clusters were also generated based on age, sex, and body mass index (BMI). Changes in the concentration of antiviral nucleosides were associated with either other metabolites or clinical variables. Increased kynurenines and reduced trigonelline excretion indicated a disrupted nicotinamide adenine nucleotide (NAD ) and sirtuin 1 (SIRT1) pathway. Our results confirm the potential of urinary metabolomics for noninvasive diagnostic/prognostic screening and show that the antiviral nucleosides could represent novel biomarkers linking viral load, immune response, and metabolism. Moreover, we established for the first time a casual link between kynurenine accumulation and deranged NAD /SIRT1, offering a novel mechanism through which SARS-CoV-2 manipulates host physiology.
AbstractList The stratification of individuals suffering from acute and post-acute SARS-CoV-2 infection remains a critical challenge. Notably, biomarkers able to specifically monitor viral progression, providing details about patient clinical status, are still not available. Herein, quantitative metabolomics is progressively recognized as a useful tool to describe the consequences of virus-host interactions considering also clinical metadata.The present study characterized the urinary metabolic profile of 243 infected individuals by quantitative nuclear magnetic resonance (NMR) spectroscopy and liquid chromatography mass spectrometry (LC–MS). Results were compared with a historical cohort of noninfected subjects. Moreover, we assessed the concentration of recently identified antiviral nucleosides and their association with other metabolites and clinical data.Urinary metabolomics can stratify patients into classes of disease severity, with a discrimination ability comparable to that of clinical biomarkers. Kynurenines showed the highest fold change in clinically-deteriorated patients and higher-risk subjects. Unique metabolite clusters were also generated based on age, sex, and body mass index (BMI). Changes in the concentration of antiviral nucleosides were associated with either other metabolites or clinical variables. Increased kynurenines and reduced trigonelline excretion indicated a disrupted nicotinamide adenine nucleotide (NAD+) and sirtuin 1 (SIRT1) pathway.Our results confirm the potential of urinary metabolomics for noninvasive diagnostic/prognostic screening and show that the antiviral nucleosides could represent novel biomarkers linking viral load, immune response, and metabolism. Moreover, we established for the first time a casual link between kynurenine accumulation and deranged NAD+/SIRT1, offering a novel mechanism through which SARS-CoV-2 manipulates host physiology.
The stratification of individuals suffering from acute and post-acute SARS-CoV-2 infection remains a critical challenge. Notably, biomarkers able to specifically monitor viral progression, providing details about patient clinical status, are still not available. Herein, quantitative metabolomics is progressively recognized as a useful tool to describe the consequences of virus-host interactions considering also clinical metadata.OBJECTIVESThe stratification of individuals suffering from acute and post-acute SARS-CoV-2 infection remains a critical challenge. Notably, biomarkers able to specifically monitor viral progression, providing details about patient clinical status, are still not available. Herein, quantitative metabolomics is progressively recognized as a useful tool to describe the consequences of virus-host interactions considering also clinical metadata.The present study characterized the urinary metabolic profile of 243 infected individuals by quantitative nuclear magnetic resonance (NMR) spectroscopy and liquid chromatography mass spectrometry (LC-MS). Results were compared with a historical cohort of noninfected subjects. Moreover, we assessed the concentration of recently identified antiviral nucleosides and their association with other metabolites and clinical data.METHODSThe present study characterized the urinary metabolic profile of 243 infected individuals by quantitative nuclear magnetic resonance (NMR) spectroscopy and liquid chromatography mass spectrometry (LC-MS). Results were compared with a historical cohort of noninfected subjects. Moreover, we assessed the concentration of recently identified antiviral nucleosides and their association with other metabolites and clinical data.Urinary metabolomics can stratify patients into classes of disease severity, with a discrimination ability comparable to that of clinical biomarkers. Kynurenines showed the highest fold change in clinically-deteriorated patients and higher-risk subjects. Unique metabolite clusters were also generated based on age, sex, and body mass index (BMI). Changes in the concentration of antiviral nucleosides were associated with either other metabolites or clinical variables. Increased kynurenines and reduced trigonelline excretion indicated a disrupted nicotinamide adenine nucleotide (NAD+) and sirtuin 1 (SIRT1) pathway.RESULTSUrinary metabolomics can stratify patients into classes of disease severity, with a discrimination ability comparable to that of clinical biomarkers. Kynurenines showed the highest fold change in clinically-deteriorated patients and higher-risk subjects. Unique metabolite clusters were also generated based on age, sex, and body mass index (BMI). Changes in the concentration of antiviral nucleosides were associated with either other metabolites or clinical variables. Increased kynurenines and reduced trigonelline excretion indicated a disrupted nicotinamide adenine nucleotide (NAD+) and sirtuin 1 (SIRT1) pathway.Our results confirm the potential of urinary metabolomics for noninvasive diagnostic/prognostic screening and show that the antiviral nucleosides could represent novel biomarkers linking viral load, immune response, and metabolism. Moreover, we established for the first time a casual link between kynurenine accumulation and deranged NAD+/SIRT1, offering a novel mechanism through which SARS-CoV-2 manipulates host physiology.CONCLUSIONSOur results confirm the potential of urinary metabolomics for noninvasive diagnostic/prognostic screening and show that the antiviral nucleosides could represent novel biomarkers linking viral load, immune response, and metabolism. Moreover, we established for the first time a casual link between kynurenine accumulation and deranged NAD+/SIRT1, offering a novel mechanism through which SARS-CoV-2 manipulates host physiology.
The stratification of individuals suffering from acute and post-acute SARS-CoV-2 infection remains a critical challenge. Notably, biomarkers able to specifically monitor viral progression, providing details about patient clinical status, are still not available. Herein, quantitative metabolomics is progressively recognized as a useful tool to describe the consequences of virus-host interactions considering also clinical metadata. The present study characterized the urinary metabolic profile of 243 infected individuals by quantitative nuclear magnetic resonance (NMR) spectroscopy and liquid chromatography mass spectrometry (LC-MS). Results were compared with a historical cohort of noninfected subjects. Moreover, we assessed the concentration of recently identified antiviral nucleosides and their association with other metabolites and clinical data. Urinary metabolomics can stratify patients into classes of disease severity, with a discrimination ability comparable to that of clinical biomarkers. Kynurenines showed the highest fold change in clinically-deteriorated patients and higher-risk subjects. Unique metabolite clusters were also generated based on age, sex, and body mass index (BMI). Changes in the concentration of antiviral nucleosides were associated with either other metabolites or clinical variables. Increased kynurenines and reduced trigonelline excretion indicated a disrupted nicotinamide adenine nucleotide (NAD ) and sirtuin 1 (SIRT1) pathway. Our results confirm the potential of urinary metabolomics for noninvasive diagnostic/prognostic screening and show that the antiviral nucleosides could represent novel biomarkers linking viral load, immune response, and metabolism. Moreover, we established for the first time a casual link between kynurenine accumulation and deranged NAD /SIRT1, offering a novel mechanism through which SARS-CoV-2 manipulates host physiology.
Author Schäfer, Hartmut
Lonati, Caterina
Gray, Nicola
Merle, Uta
Kulkarni, Aditi
Wist, Julien
Trautwein, Christoph
Singh, Yogesh
Nicholson, Jeremy
Zizmare, Laimdota
Lodge, Samantha
Cannet, Claire
Sala, Samuele
Bucci, Daniele
Masuda, Reika
Nitschke, Philipp
Berezhnoy, Georgy
Lawler, Nathan
Author_xml – sequence: 1
  givenname: Caterina
  surname: Lonati
  fullname: Lonati, Caterina
  organization: Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University Hospital Tübingen, Tübingen, Germany
– sequence: 2
  givenname: Georgy
  surname: Berezhnoy
  fullname: Berezhnoy, Georgy
  organization: Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University Hospital Tübingen, Tübingen, Germany
– sequence: 3
  givenname: Nathan
  surname: Lawler
  fullname: Lawler, Nathan
  organization: Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University Perth, Australia
– sequence: 4
  givenname: Reika
  surname: Masuda
  fullname: Masuda, Reika
  organization: Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University Perth, Australia
– sequence: 5
  givenname: Aditi
  surname: Kulkarni
  fullname: Kulkarni, Aditi
  organization: Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University Hospital Tübingen, Tübingen, Germany
– sequence: 6
  givenname: Samuele
  surname: Sala
  fullname: Sala, Samuele
  organization: Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University Perth, Australia
– sequence: 7
  givenname: Philipp
  surname: Nitschke
  fullname: Nitschke, Philipp
  organization: Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University Perth, Australia
– sequence: 8
  givenname: Laimdota
  surname: Zizmare
  fullname: Zizmare, Laimdota
  organization: Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University Hospital Tübingen, Tübingen, Germany
– sequence: 9
  givenname: Daniele
  surname: Bucci
  fullname: Bucci, Daniele
  organization: Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University Hospital Tübingen, Tübingen, Germany
– sequence: 10
  givenname: Claire
  surname: Cannet
  fullname: Cannet, Claire
  organization: Bruker BioSpin GmbH, AIC Division, Ettlingen, Germany
– sequence: 11
  givenname: Hartmut
  surname: Schäfer
  fullname: Schäfer, Hartmut
  organization: Bruker BioSpin GmbH, AIC Division, Ettlingen, Germany
– sequence: 12
  givenname: Yogesh
  surname: Singh
  fullname: Singh, Yogesh
  organization: Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen, Tübingen, Germany
– sequence: 13
  givenname: Nicola
  surname: Gray
  fullname: Gray, Nicola
  organization: Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University Perth, Australia
– sequence: 14
  givenname: Samantha
  surname: Lodge
  fullname: Lodge, Samantha
  organization: Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University Perth, Australia
– sequence: 15
  givenname: Jeremy
  surname: Nicholson
  fullname: Nicholson, Jeremy
  organization: Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University Perth, Australia
– sequence: 16
  givenname: Uta
  surname: Merle
  fullname: Merle, Uta
  email: Uta.Merle@med.uni-heidelberg.de
  organization: Department of Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany
– sequence: 17
  givenname: Julien
  surname: Wist
  fullname: Wist, Julien
  email: Julien.Wist@murdoch.edu.au
  organization: Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University Perth, Australia
– sequence: 18
  givenname: Christoph
  orcidid: 0000-0003-4672-6395
  surname: Trautwein
  fullname: Trautwein, Christoph
  email: christoph.trautwein@med.uni-tuebingen.de
  organization: Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University Hospital Tübingen, Tübingen, Germany
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37955280$$D View this record in MEDLINE/PubMed
BookMark eNp1kUtr3DAUhUVJaR7ttssi6KYQnOppydDNMH0FQguZpFsjy_KMgi25kpxhfkf-cOWZtIXQrnQQ37n3cs4pOHLeGQBeY3SBOebvte6HgiBCC4yweAZOMKOiYJTio71mRVkSfAxOY7xDCHPOxAtwTEXFOZHoBDzcButU2MFxY5xPu9G6NfQdXC2uV8XS_ygItK4zOlnvoPbOZRmh7q2zWvWwtWrtfExWR7i1aQMHk1Tjez_MP8q1cHLa35sQoR1GZYNp4bfFx3M4qrTZqt0eWV1e32Co8o57Ne95CZ53qo_m1eN7Bm4_f7pZfi2uvn-5XC6uCs1wmQpsVEV42yBaamMaQYTRquNKsIbpUlLJlW6RYW2FRVO1jPFOy0pyZISWLNvOwLvD3DH4n5OJqR5s1KbvlTN-ijWRsuJSMiYy-vYJeuen4PJ1Nako5rRCFc_Um0dqagbT1mOwQ862_h13Bi4OgA4-xmC6PwhG9dxnPfdZz33Wc5_ZwJ4YtE37kFJQtv-_7cPBtlV9MqE16zDtsvh79b-NJWFCIPoLEDG5ZA
CitedBy_id crossref_primary_10_3390_metabo14120724
crossref_primary_10_3390_ani14020273
Cites_doi 10.1055/s-0042-1759567
10.1038/d41586-021-00396-2
10.1371/journal.pone.0060409
10.1038/s41392-022-01257-8
10.3389/fimmu.2022.831168
10.1159/000503030
10.1021/ac981422i
10.1038/s41591-021-01283-z
10.1515/cclm-2021-0414
10.3390/metabo9100198
10.3389/fmicb.2015.01151
10.1021/acs.analchem.1c05389
10.1021/ja055336t
10.1016/j.bbabio.2016.03.012
10.1530/JME-18-0085
10.1021/acs.analchem.0c04952
10.1007/s11306-021-01859-3
10.1016/j.cell.2020.05.032
10.1126/science.1202007
10.1021/acs.jproteome.0c00876
10.1038/s41598-021-90610-y
10.1038/s41467-021-21907-9
10.1080/22221751.2020.1736644
10.1189/jlb.1112557
10.4103/abr.abr_303_20
10.1074/jbc.RA120.015138
10.1007/s43657-021-00020-3
10.1101/2023.05.08.23289637
10.3389/fmolb.2023.1158330
10.2147/JIR.S325853
10.3389/fmolb.2023.1111482
10.18632/aging.103344
10.1038/s41419-022-04861-2
10.1038/s41598-019-49685-x
10.1038/s41590-018-0255-3
10.1016/j.cmet.2018.02.011
10.1038/s41366-021-00804-7
10.3390/metabo13030364
10.3390/biom13010163
10.1007/s11357-013-9510-6
10.3390/metabo12121277
10.1016/j.bbadis.2015.08.017
10.1371/journal.ppat.1007756
10.3389/fimmu.2020.00031
10.1038/s41598-020-73966-5
10.1016/j.celrep.2021.110271
10.1007/s11306-023-01971-6
10.1093/ofid/ofac063
10.1021/ac5025039
10.3389/fimmu.2021.634416
10.1016/j.pcd.2021.04.004
10.1021/acs.jproteome.1c00052
10.3390/ijerph18189739
10.1128/mBio.02249-14
10.1016/j.isci.2020.101645
10.1021/ac048630x
10.3389/fendo.2020.569241
10.1016/j.talanta.2020.121872
10.1016/j.it.2022.02.001
10.3390/metabo11010044
10.1373/clinchem.2014.232918
10.1016/j.cmet.2015.12.009
10.3389/fendo.2018.00614
10.3390/cells10020460
10.3390/biomedicines10030538
10.1111/acem.14447
10.1016/j.xcrm.2021.100369
10.1126/scisignal.abf8483
10.3390/ijms22179548
10.1021/acs.jproteome.1c00224
10.1038/s41598-022-14292-w
10.3389/fimmu.2022.1004545
10.1111/j.2517-6161.1995.tb02031.x
10.14309/ctg.0000000000000524
10.1038/s42255-018-0014-7
10.1007/s00018-015-2119-4
10.1038/s41590-019-0353-x
10.1093/ofid/ofab483
10.1038/s41419-021-03540-y
10.1038/s41392-021-00822-x
10.1172/jci.insight.140327
ContentType Journal Article
Copyright 2023 the author(s), published by De Gruyter, Berlin/Boston.
2024. This work is published under http://creativecommons.org/licenses/by/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2023 the author(s), published by De Gruyter, Berlin/Boston.
– notice: 2024. This work is published under http://creativecommons.org/licenses/by/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QO
7T7
7TK
7U7
8FD
C1K
FR3
P64
7X8
DOI 10.1515/cclm-2023-1017
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Biotechnology Research Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Neurosciences Abstracts
Toxicology Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Biotechnology Research Abstracts
Technology Research Database
Toxicology Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList Biotechnology Research Abstracts
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
EISSN 1437-4331
EndPage 788
ExternalDocumentID 37955280
10_1515_cclm_2023_1017
10_1515_cclm_2023_1017624770
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Siemens
  grantid: Unassigned
– fundername: Werner Siemens-Stiftung
  grantid: Werner Siemens Imaging Center
GroupedDBID ---
0R~
0~D
29B
354
36B
4.4
53G
5GY
5RE
AAAEU
AABBZ
AAFPC
AAGVJ
AAILP
AALGR
AAOQK
AAOWA
AAPJK
AAQCX
AARRE
AASQH
AAXCG
ABAOT
ABAQN
ABDRH
ABFKT
ABFQV
ABIQR
ABJNI
ABLJU
ABMIY
ABPLS
ABRDF
ABUVI
ABWLS
ABXMZ
ABYBW
ACDEB
ACEFL
ACGFS
ACIWK
ACPMA
ACPRK
ACUND
ACYCL
ACZBO
ADDWE
ADEQT
ADGQD
ADGYE
ADOZN
AECWL
AEDGQ
AEGVQ
AEICA
AEJTT
AENEX
AEQDQ
AERZL
AEXIE
AFBAA
AFBDD
AFBQV
AFCXV
AFGDO
AFQUK
AFRAH
AFYRI
AGBEV
AHOVO
AHVWV
AHXUK
AIERV
AIWOI
AJATJ
AJHHK
AKXKS
ALMA_UNASSIGNED_HOLDINGS
ALUKF
ALYBR
ASYPN
BAKPI
BBCWN
BCIFA
CGQUA
CS3
DU5
EBS
EMOBN
F5P
HZ~
IY9
KDIRW
N9A
O9-
OBC
OBS
OEB
OES
OHH
P2P
PQQKQ
QD8
RDG
SA.
SLJYH
TEORI
UK5
WTRAM
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QO
7T7
7TK
7U7
8FD
ADNPR
C1K
FR3
P64
7X8
ID FETCH-LOGICAL-c416t-1ea925db036ceeb727ecaf5a74b4c68385acd0e4d917b9d445fc89850e7c84b03
ISSN 1434-6621
1437-4331
IngestDate Wed Jul 30 11:30:37 EDT 2025
Wed Aug 13 08:57:15 EDT 2025
Wed Jul 16 06:53:23 EDT 2025
Thu Apr 24 22:53:42 EDT 2025
Tue Jul 01 02:49:42 EDT 2025
Thu Jul 10 10:28:32 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords COVID-19
precision diagnostics
kynurenine pathway
sirtuins
antiviral nucleosides
Language English
License This work is licensed under the Creative Commons Attribution 4.0 International License.
http://creativecommons.org/licenses/by/4.0
2023 the author(s), published by De Gruyter, Berlin/Boston.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c416t-1ea925db036ceeb727ecaf5a74b4c68385acd0e4d917b9d445fc89850e7c84b03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-4672-6395
OpenAccessLink https://proxy.k.utb.cz/login?url=https://www.degruyter.com/document/doi/10.1515/cclm-2023-1017/pdf
PMID 37955280
PQID 2931539095
PQPubID 105421
PageCount 19
ParticipantIDs proquest_miscellaneous_2889588447
proquest_journals_2931539095
pubmed_primary_37955280
crossref_primary_10_1515_cclm_2023_1017
crossref_citationtrail_10_1515_cclm_2023_1017
walterdegruyter_journals_10_1515_cclm_2023_1017624770
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-03-25
PublicationDateYYYYMMDD 2024-03-25
PublicationDate_xml – month: 03
  year: 2024
  text: 2024-03-25
  day: 25
PublicationDecade 2020
PublicationPlace Germany
PublicationPlace_xml – name: Germany
– name: Berlin
PublicationTitle Clinical chemistry and laboratory medicine
PublicationTitleAlternate Clin Chem Lab Med
PublicationYear 2024
Publisher De Gruyter
Walter De Gruyter & Company
Publisher_xml – name: De Gruyter
– name: Walter De Gruyter & Company
References 2024022613070237323_j_cclm-2023-1017_ref_032
2024022613070237323_j_cclm-2023-1017_ref_076
2024022613070237323_j_cclm-2023-1017_ref_033
2024022613070237323_j_cclm-2023-1017_ref_077
2024022613070237323_j_cclm-2023-1017_ref_034
2024022613070237323_j_cclm-2023-1017_ref_078
2024022613070237323_j_cclm-2023-1017_ref_035
2024022613070237323_j_cclm-2023-1017_ref_079
2024022613070237323_j_cclm-2023-1017_ref_036
2024022613070237323_j_cclm-2023-1017_ref_037
2024022613070237323_j_cclm-2023-1017_ref_038
2024022613070237323_j_cclm-2023-1017_ref_039
2024022613070237323_j_cclm-2023-1017_ref_080
2024022613070237323_j_cclm-2023-1017_ref_081
2024022613070237323_j_cclm-2023-1017_ref_082
2024022613070237323_j_cclm-2023-1017_ref_083
2024022613070237323_j_cclm-2023-1017_ref_040
2024022613070237323_j_cclm-2023-1017_ref_084
2024022613070237323_j_cclm-2023-1017_ref_041
2024022613070237323_j_cclm-2023-1017_ref_042
2024022613070237323_j_cclm-2023-1017_ref_007
2024022613070237323_j_cclm-2023-1017_ref_008
2024022613070237323_j_cclm-2023-1017_ref_009
2024022613070237323_j_cclm-2023-1017_ref_043
2024022613070237323_j_cclm-2023-1017_ref_044
2024022613070237323_j_cclm-2023-1017_ref_001
2024022613070237323_j_cclm-2023-1017_ref_045
2024022613070237323_j_cclm-2023-1017_ref_002
2024022613070237323_j_cclm-2023-1017_ref_046
2024022613070237323_j_cclm-2023-1017_ref_003
2024022613070237323_j_cclm-2023-1017_ref_047
2024022613070237323_j_cclm-2023-1017_ref_004
2024022613070237323_j_cclm-2023-1017_ref_048
2024022613070237323_j_cclm-2023-1017_ref_005
2024022613070237323_j_cclm-2023-1017_ref_049
2024022613070237323_j_cclm-2023-1017_ref_006
2024022613070237323_j_cclm-2023-1017_ref_050
2024022613070237323_j_cclm-2023-1017_ref_051
2024022613070237323_j_cclm-2023-1017_ref_052
2024022613070237323_j_cclm-2023-1017_ref_053
2024022613070237323_j_cclm-2023-1017_ref_018
2024022613070237323_j_cclm-2023-1017_ref_019
2024022613070237323_j_cclm-2023-1017_ref_010
2024022613070237323_j_cclm-2023-1017_ref_054
2024022613070237323_j_cclm-2023-1017_ref_011
2024022613070237323_j_cclm-2023-1017_ref_055
2024022613070237323_j_cclm-2023-1017_ref_012
2024022613070237323_j_cclm-2023-1017_ref_056
2024022613070237323_j_cclm-2023-1017_ref_013
2024022613070237323_j_cclm-2023-1017_ref_057
2024022613070237323_j_cclm-2023-1017_ref_014
2024022613070237323_j_cclm-2023-1017_ref_058
2024022613070237323_j_cclm-2023-1017_ref_015
2024022613070237323_j_cclm-2023-1017_ref_059
2024022613070237323_j_cclm-2023-1017_ref_016
2024022613070237323_j_cclm-2023-1017_ref_017
2024022613070237323_j_cclm-2023-1017_ref_060
2024022613070237323_j_cclm-2023-1017_ref_061
2024022613070237323_j_cclm-2023-1017_ref_062
2024022613070237323_j_cclm-2023-1017_ref_063
2024022613070237323_j_cclm-2023-1017_ref_020
2024022613070237323_j_cclm-2023-1017_ref_064
2024022613070237323_j_cclm-2023-1017_ref_029
2024022613070237323_j_cclm-2023-1017_ref_021
2024022613070237323_j_cclm-2023-1017_ref_065
2024022613070237323_j_cclm-2023-1017_ref_022
2024022613070237323_j_cclm-2023-1017_ref_066
2024022613070237323_j_cclm-2023-1017_ref_023
2024022613070237323_j_cclm-2023-1017_ref_067
2024022613070237323_j_cclm-2023-1017_ref_024
2024022613070237323_j_cclm-2023-1017_ref_068
2024022613070237323_j_cclm-2023-1017_ref_025
2024022613070237323_j_cclm-2023-1017_ref_069
2024022613070237323_j_cclm-2023-1017_ref_026
2024022613070237323_j_cclm-2023-1017_ref_027
2024022613070237323_j_cclm-2023-1017_ref_028
2024022613070237323_j_cclm-2023-1017_ref_070
2024022613070237323_j_cclm-2023-1017_ref_071
2024022613070237323_j_cclm-2023-1017_ref_072
2024022613070237323_j_cclm-2023-1017_ref_073
2024022613070237323_j_cclm-2023-1017_ref_030
2024022613070237323_j_cclm-2023-1017_ref_074
2024022613070237323_j_cclm-2023-1017_ref_031
2024022613070237323_j_cclm-2023-1017_ref_075
References_xml – ident: 2024022613070237323_j_cclm-2023-1017_ref_059
  doi: 10.1055/s-0042-1759567
– ident: 2024022613070237323_j_cclm-2023-1017_ref_002
  doi: 10.1038/d41586-021-00396-2
– ident: 2024022613070237323_j_cclm-2023-1017_ref_069
  doi: 10.1371/journal.pone.0060409
– ident: 2024022613070237323_j_cclm-2023-1017_ref_042
  doi: 10.1038/s41392-022-01257-8
– ident: 2024022613070237323_j_cclm-2023-1017_ref_043
  doi: 10.3389/fimmu.2022.831168
– ident: 2024022613070237323_j_cclm-2023-1017_ref_080
  doi: 10.1159/000503030
– ident: 2024022613070237323_j_cclm-2023-1017_ref_051
  doi: 10.1021/ac981422i
– ident: 2024022613070237323_j_cclm-2023-1017_ref_003
  doi: 10.1038/s41591-021-01283-z
– ident: 2024022613070237323_j_cclm-2023-1017_ref_013
  doi: 10.1515/cclm-2021-0414
– ident: 2024022613070237323_j_cclm-2023-1017_ref_054
  doi: 10.3390/metabo9100198
– ident: 2024022613070237323_j_cclm-2023-1017_ref_068
  doi: 10.3389/fmicb.2015.01151
– ident: 2024022613070237323_j_cclm-2023-1017_ref_029
  doi: 10.1021/acs.analchem.1c05389
– ident: 2024022613070237323_j_cclm-2023-1017_ref_052
  doi: 10.1021/ja055336t
– ident: 2024022613070237323_j_cclm-2023-1017_ref_067
  doi: 10.1016/j.bbabio.2016.03.012
– ident: 2024022613070237323_j_cclm-2023-1017_ref_038
  doi: 10.1530/JME-18-0085
– ident: 2024022613070237323_j_cclm-2023-1017_ref_031
  doi: 10.1021/acs.analchem.0c04952
– ident: 2024022613070237323_j_cclm-2023-1017_ref_024
  doi: 10.1007/s11306-021-01859-3
– ident: 2024022613070237323_j_cclm-2023-1017_ref_022
  doi: 10.1016/j.cell.2020.05.032
– ident: 2024022613070237323_j_cclm-2023-1017_ref_064
  doi: 10.1126/science.1202007
– ident: 2024022613070237323_j_cclm-2023-1017_ref_016
  doi: 10.1021/acs.jproteome.0c00876
– ident: 2024022613070237323_j_cclm-2023-1017_ref_035
  doi: 10.1038/s41598-021-90610-y
– ident: 2024022613070237323_j_cclm-2023-1017_ref_005
  doi: 10.1038/s41467-021-21907-9
– ident: 2024022613070237323_j_cclm-2023-1017_ref_007
  doi: 10.1080/22221751.2020.1736644
– ident: 2024022613070237323_j_cclm-2023-1017_ref_041
  doi: 10.1189/jlb.1112557
– ident: 2024022613070237323_j_cclm-2023-1017_ref_078
  doi: 10.4103/abr.abr_303_20
– ident: 2024022613070237323_j_cclm-2023-1017_ref_061
  doi: 10.1074/jbc.RA120.015138
– ident: 2024022613070237323_j_cclm-2023-1017_ref_030
  doi: 10.1007/s43657-021-00020-3
– ident: 2024022613070237323_j_cclm-2023-1017_ref_032
  doi: 10.1101/2023.05.08.23289637
– ident: 2024022613070237323_j_cclm-2023-1017_ref_048
  doi: 10.3389/fmolb.2023.1158330
– ident: 2024022613070237323_j_cclm-2023-1017_ref_072
  doi: 10.2147/JIR.S325853
– ident: 2024022613070237323_j_cclm-2023-1017_ref_012
  doi: 10.3389/fmolb.2023.1111482
– ident: 2024022613070237323_j_cclm-2023-1017_ref_084
  doi: 10.18632/aging.103344
– ident: 2024022613070237323_j_cclm-2023-1017_ref_063
  doi: 10.1038/s41419-022-04861-2
– ident: 2024022613070237323_j_cclm-2023-1017_ref_047
  doi: 10.1038/s41598-019-49685-x
– ident: 2024022613070237323_j_cclm-2023-1017_ref_076
  doi: 10.1038/s41590-018-0255-3
– ident: 2024022613070237323_j_cclm-2023-1017_ref_083
  doi: 10.1016/j.cmet.2018.02.011
– ident: 2024022613070237323_j_cclm-2023-1017_ref_027
  doi: 10.1038/s41366-021-00804-7
– ident: 2024022613070237323_j_cclm-2023-1017_ref_037
  doi: 10.3390/metabo13030364
– ident: 2024022613070237323_j_cclm-2023-1017_ref_033
  doi: 10.3390/biom13010163
– ident: 2024022613070237323_j_cclm-2023-1017_ref_056
  doi: 10.1007/s11357-013-9510-6
– ident: 2024022613070237323_j_cclm-2023-1017_ref_011
  doi: 10.3390/metabo12121277
– ident: 2024022613070237323_j_cclm-2023-1017_ref_044
  doi: 10.1016/j.bbadis.2015.08.017
– ident: 2024022613070237323_j_cclm-2023-1017_ref_079
  doi: 10.1371/journal.ppat.1007756
– ident: 2024022613070237323_j_cclm-2023-1017_ref_039
  doi: 10.3389/fimmu.2020.00031
– ident: 2024022613070237323_j_cclm-2023-1017_ref_077
  doi: 10.1038/s41598-020-73966-5
– ident: 2024022613070237323_j_cclm-2023-1017_ref_036
  doi: 10.1016/j.celrep.2021.110271
– ident: 2024022613070237323_j_cclm-2023-1017_ref_034
  doi: 10.1007/s11306-023-01971-6
– ident: 2024022613070237323_j_cclm-2023-1017_ref_046
  doi: 10.1093/ofid/ofac063
– ident: 2024022613070237323_j_cclm-2023-1017_ref_057
– ident: 2024022613070237323_j_cclm-2023-1017_ref_049
  doi: 10.1021/ac5025039
– ident: 2024022613070237323_j_cclm-2023-1017_ref_060
  doi: 10.3389/fimmu.2021.634416
– ident: 2024022613070237323_j_cclm-2023-1017_ref_071
  doi: 10.1016/j.pcd.2021.04.004
– ident: 2024022613070237323_j_cclm-2023-1017_ref_018
  doi: 10.1021/acs.jproteome.1c00052
– ident: 2024022613070237323_j_cclm-2023-1017_ref_001
– ident: 2024022613070237323_j_cclm-2023-1017_ref_008
  doi: 10.3390/ijerph18189739
– ident: 2024022613070237323_j_cclm-2023-1017_ref_040
  doi: 10.1128/mBio.02249-14
– ident: 2024022613070237323_j_cclm-2023-1017_ref_015
  doi: 10.1016/j.isci.2020.101645
– ident: 2024022613070237323_j_cclm-2023-1017_ref_050
  doi: 10.1021/ac048630x
– ident: 2024022613070237323_j_cclm-2023-1017_ref_004
  doi: 10.3389/fendo.2020.569241
– ident: 2024022613070237323_j_cclm-2023-1017_ref_053
  doi: 10.1016/j.talanta.2020.121872
– ident: 2024022613070237323_j_cclm-2023-1017_ref_075
  doi: 10.1016/j.it.2022.02.001
– ident: 2024022613070237323_j_cclm-2023-1017_ref_010
  doi: 10.3390/metabo11010044
– ident: 2024022613070237323_j_cclm-2023-1017_ref_028
  doi: 10.1373/clinchem.2014.232918
– ident: 2024022613070237323_j_cclm-2023-1017_ref_065
  doi: 10.1016/j.cmet.2015.12.009
– ident: 2024022613070237323_j_cclm-2023-1017_ref_081
  doi: 10.3389/fendo.2018.00614
– ident: 2024022613070237323_j_cclm-2023-1017_ref_045
  doi: 10.3390/cells10020460
– ident: 2024022613070237323_j_cclm-2023-1017_ref_066
  doi: 10.3390/biomedicines10030538
– ident: 2024022613070237323_j_cclm-2023-1017_ref_058
  doi: 10.1111/acem.14447
– ident: 2024022613070237323_j_cclm-2023-1017_ref_009
  doi: 10.1016/j.xcrm.2021.100369
– ident: 2024022613070237323_j_cclm-2023-1017_ref_020
  doi: 10.1126/scisignal.abf8483
– ident: 2024022613070237323_j_cclm-2023-1017_ref_025
  doi: 10.3390/ijms22179548
– ident: 2024022613070237323_j_cclm-2023-1017_ref_006
  doi: 10.1021/acs.jproteome.1c00224
– ident: 2024022613070237323_j_cclm-2023-1017_ref_019
  doi: 10.1038/s41598-022-14292-w
– ident: 2024022613070237323_j_cclm-2023-1017_ref_021
  doi: 10.3389/fimmu.2022.1004545
– ident: 2024022613070237323_j_cclm-2023-1017_ref_055
  doi: 10.1111/j.2517-6161.1995.tb02031.x
– ident: 2024022613070237323_j_cclm-2023-1017_ref_062
  doi: 10.14309/ctg.0000000000000524
– ident: 2024022613070237323_j_cclm-2023-1017_ref_026
  doi: 10.1038/s42255-018-0014-7
– ident: 2024022613070237323_j_cclm-2023-1017_ref_073
  doi: 10.1007/s00018-015-2119-4
– ident: 2024022613070237323_j_cclm-2023-1017_ref_074
  doi: 10.1038/s41590-019-0353-x
– ident: 2024022613070237323_j_cclm-2023-1017_ref_082
  doi: 10.1093/ofid/ofab483
– ident: 2024022613070237323_j_cclm-2023-1017_ref_017
  doi: 10.1038/s41419-021-03540-y
– ident: 2024022613070237323_j_cclm-2023-1017_ref_070
  doi: 10.1038/s41392-021-00822-x
– ident: 2024022613070237323_j_cclm-2023-1017_ref_014
– ident: 2024022613070237323_j_cclm-2023-1017_ref_023
  doi: 10.1172/jci.insight.140327
SSID ssj0015547
Score 2.4419498
Snippet The stratification of individuals suffering from acute and post-acute SARS-CoV-2 infection remains a critical challenge. Notably, biomarkers able to...
SourceID proquest
pubmed
crossref
walterdegruyter
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 770
SubjectTerms Adenine
Antiviral Agents
Antiviral drugs
antiviral nucleosides
Biomarkers
Biomarkers - urine
Body mass index
Body size
COVID-19
COVID-19 - diagnosis
COVID-19 Testing
Genotype & phenotype
Humans
Immune response
kynurenine pathway
Liquid chromatography
Mass spectrometry
Mass spectroscopy
Medical diagnosis
Metabolites
Metabolomics
Metabolomics - methods
NAD
Nicotinamide
NMR
NMR spectroscopy
Nuclear magnetic resonance
Nucleosides
Nucleotides
Phenotyping
precision diagnostics
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
SIRT1 protein
Sirtuin 1
sirtuins
Spectrum analysis
Viral diseases
Title Urinary phenotyping of SARS-CoV-2 infection connects clinical diagnostics with metabolomics and uncovers impaired NAD+ pathway and SIRT1 activation
URI https://www.degruyter.com/doi/10.1515/cclm-2023-1017
https://www.ncbi.nlm.nih.gov/pubmed/37955280
https://www.proquest.com/docview/2931539095
https://www.proquest.com/docview/2889588447
Volume 62
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FVuJxqKC8AgUtEogDchs769cxDYWC2hyapOrNWq_XNCJNqsQhav8Gv5R_wMw-bDctCHqxImcfTubz7szsNzOEvM391GU5vN-eywOHeTLGYGXX4SJ3My-Tgqn6KYe9YH_Ivp74J43GrxpraVGk2-LyxriS20gV7oFcMUr2PyRbDgo34DPIF64gYbj-k4yHMx1NizytaXFxbhjM_c5R3-lOjx2v5Foh2RxWVGRulLGQmWbZqTzNyh17JguAxBjjlHXmZtjzkOE5V7GUI2Sq9zof33m7mI31dMl16qb-l6OBq3Jy_KikbHMf2LmErSunuhjk4fH-6tn-AXrzRyY2EUMTK4eBnMnL04n2HSpXfnkacMCXJqCxp44CKjf7fJEZ7Xj0ndc9HB5DipeOhtY0FXhdZosLy1bW6zRrMycIdHD1trT3wioAzCzugVcDMaut1KGuV2I2_VDXFry2n_gq9YYQ4zMH68w7uIBVO6dlC6xsqCXNEQ0sGCHB_gn2R0Id7D4MJr9D1j2wbGBpXu983t07Lo--QL9TFYHsLzSZRmGcnavPcVWTumYePSAbS8W4yOQ3_ffVFKfBQ7JhLB7a0fB9RBpysknudS0gNsndQ4OBx-SnQTStIZpOc1ohmpaIphbR1CKa1hBNEdG0jmgKyKMW0dQimgKiP1CDZ9VE4ZlWeH5Chp_2Bt19x5QNcQRYF4XjSh57fpaCbgYaYAoKuhQ893nIUiaCqB35XGQtybLYDdM4YwxpjHHkt2QoIgbdnpK1yXQinxMaxQxtojj1OGdRq83jQOacpZkvhQxz3iSOFUEiTE59LO0yTm4WfZO8L9uf62wyf2y5ZSWamBVnnoBqDgpKDFZRk7wpvwZp4SEfn8jpAtpEUYzB5wyGeKaRUE7VDmPf96JWk_gr0Kjm-BtmX9yy30tyv3qvt8haMVvIV6DLF-lrg_7f1xL6AQ
linkProvider Walter de Gruyter
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFD6CTmLwMGDcCgOMhMQD8pakdi6PpWx0sPZhbae9RY7tgESboDbVVP4Gf5hzcmNs8ALPviS2T3KO7e_7DsDrVCauSPH79lzlc-HZiMjKLlc6dY1nrBZl_pTR2B_OxMdzeX6JC0OwSmM_L9ebolJIPTC5XtNBWas1gB74QOv5glPmb14KQH8pFvObsBWSEksHtvof3h2etXcJ6DDLFCuiJ7jve24t3Xi9m99d07V48w7sXJRX2O37XfJER3dBN2OoAChf99dFsq-_X5F3_L9B3oOdOlBl_cqy7sMNm-3C9qDJD7cLt0b1tfwD-DFblrReRoCxvNgQB4vlKZv0Tyd8kJ9xjzWgr4xpgtboYsUaUiYzFdyPBKMZnQuzhS3QNudEmF4xlRmGzpegpitGpE78SRs27r9_yyid8oXalFUmx6dTlxFNozpkfgizo8PpYMjrbA9cY1BYcNeqyJMmQZeKjjvBuMpqlUoViERoP-yFUmnjWGFwg5lERghCn0WhdGygQ4HNHkEnyzP7BFhI2d5dP0o8pUTo9FTk21SJxEirbZCqLvBmoWNdS6FTRo55TFsinPqYpj6mqScIXNCFN239b5UIyF9r7jV2E9c_g1WMERX6lQiD2S68aotxtehuRmU2X2OdMIyIMyywi8eVvbWP6gWRlF7odEFeMcBfz_jz6_ieCALn6T-2ewnbw-noJD45Hn96BrexVBD6zpN70CmWa_scw7EieVF_bz8BhCsymQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7BVipwKFBeCwWMhMQBuU2yduIcl22XFugKdduqt8ixHQ5sk2o3q2r5G_xhZvICWrjA2eP32DP2fDMD8DqTqS8yPN-Br0MuAheTs7LPtcl8G1hnRJU_5XAS7p-ID2eyRRMuGlildV_my1VZR0jdsYVZ0kdZF2sAJfCOMbNzTpm_eRUA-sJmN2FNCd9TPVgbvn-3d9qZElBeVhlWxEDwMAz8JnLj9VZ-l0zX1M07sHFZWbC74f0iiMZ3IW2nUONPvm4vy3TbfLsS3fG_5ngPNho1lQ1rvroPN1y-CbdGbXa4TVg_bIzyD-D7ybxy6mUEFyvKFXlgsSJj0-HRlI-KUx6wFvKVM0PAGlMuWOuSyWwN9qNw0Yx-hdm5K5EzZ-QuvWA6twxFLwFNF4xcOvGKtmwy3H3LKJnypV5VJNODo2OfkZNG_cX8EE7Ge8ejfd7keuAGVcKS-07HgbQpClQU2ylqVc7oTOpIpMKEaqCkNtZzwuLzMo2tEIQ9i5X0XGSUwGqPoJcXuXsCTFGudz-M00BrobyBjkOXaZFa6YyLMt0H3u5zYppA6JSPY5bQgwhXPqGVT2jlCQAX9eFNR39RhwD5K-VWyzZJcxUsEtSnUKrEqMr24VVXjLtFlhmdu2KJNErF5DEssInHNbt1XQ2iWMpAeX2QV_jvZx9_Hk4YiCjynv5jvZew_nl3nHw6mHx8BrexUBD0LpBb0CvnS_ccdbEyfdGcth_BTzFA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Urinary+phenotyping+of+SARS-CoV-2+infection+connects+clinical+diagnostics+with+metabolomics+and+uncovers+impaired+NAD%2B+pathway+and+SIRT1+activation&rft.jtitle=Clinical+chemistry+and+laboratory+medicine&rft.au=Lonati%2C+Caterina&rft.au=Berezhnoy%2C+Georgy&rft.au=Lawler%2C+Nathan&rft.au=Masuda%2C+Reika&rft.date=2024-03-25&rft.pub=De+Gruyter&rft.issn=1434-6621&rft.eissn=1437-4331&rft.volume=62&rft.issue=4&rft.spage=770&rft.epage=788&rft_id=info:doi/10.1515%2Fcclm-2023-1017&rft.externalDBID=n%2Fa&rft.externalDocID=10_1515_cclm_2023_1017624770
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1434-6621&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1434-6621&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1434-6621&client=summon